ArticleFrontiers in medical technology2025
A low-cost platform for automated cervical cytology: addressing health and socioeconomic challenges in low-resource settings.
Article in Frontiers in medical technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An AI-powered self-driving microscope for low-cost acute leukemia detection.Nature communications · 2026Article
- Artificial intelligence for colposcopic and cytological image analysis in early cervical cancer detection.iScience · 2026Review
- CPSMI2025: A curated dataset of conventional Pap smear microscopy images for deep learning-based cervical cancer screening.Data in brief · 2025Article
- Transforming cervical cancer pathological diagnosis through artificial intelligence: progress, performance, and barriers to clinical implementation.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer remains a significant health challenge around the globe, with particularly high prevalence in low- and middle-income countries. This disease is preventable and curable if detected in early stages, making regular screening critically important. Cervical cytology, the most widely used screening method, has proven highly effective in reducing cervical cancer incidence and mortality in high income countries. However, its effectiveness in low-resource settings has been limited, among other factors, by insufficient diagnostic infrastructure and a shortage of trained healthcare personnel. Methods: This paper introduces the development of a low-cost microscopy platform designed to address these limitations by enabling automatic reading of cervical cytology slides. The system features a robotized microscope capable of slide scanning, autofocus, and digital image capture, while supporting the integration of artificial intelligence (AI) algorithms. All at a production cost below 500 USD. A dataset of nearly 2,000 images, captured with the custom-built microscope and covering seven distinct cervical cellular types relevant in cytologic analysis, was created. This dataset was then used to fine-tune and test several pre-trained models for classifying between images containing normal and abnormal cell subtypes. Results: Most of the tested models showed good performance for properly classifying images containing abnormal and normal cervical cells, with sensitivities above 90%. Among these models, MobileNet demonstrated the highest accuracy in detecting abnormal cell types, achieving sensitivities of 98.26% and 97.95%, specificities of 88.91% and 88.72%, and F-scores of 96.42% and 96.23% on the validation and test sets, respectively. Conclusions: The results indicate that MobileNet might be a suitable model for real-world deployment on the low-cost platform, offering high precision and efficiency in classifying cervical cytology images. This system presents a first step towards a promising solution for improving cervical cancer screening in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.